Develops, manufactures and markets a robust line of rapid diagnostic tests that address some of today's greatest healthcare challenges, including HIV and Hepatitis C.
  • Demo Video
  • Private Messages
  • Edit My Profile
  • View/Edit Portfolio

AGORACOM News Flash

AGORACOM WIRE - FRIDAY MAY 25TH, 2012

FOCUS METALS (TSXV:FMS) Changes Its Name to Focus Graphite Inc.

  • Aim to develop and manufacture the best technology graphite in the world
  • Additional shareholder value will come from investment in commercialized graphene through joint venture partner, Grafoid Inc.

Read More   |   *SPONSOR

INTERNATIONAL PBX VENTURES (TSX:PBX) Signs Copaquire Joint Venture Option Agreement - $90M Potential Payment Read More

AGORACOM Maintenance Alert: Friday Evening Downtime for About an Hour Read More

LOMIKO METALS (TSXV:LMR) Graphite and Zinc Price Outlook is Favourable Through 2013  Read More   |   *SPONSOR

 

 

Message: "The market is big; you're looking at many millions of users

Generic_profile
Rank: [?]
Treasurer
Points: [?]
569
Rating: [?]
Votes: 22 Score: 3.4
  • Currently 3.4/5 Stars.
Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.

"The market is big; you're looking at many millions of users

posted on Apr 10, 10 09:39AM

Building A Handheld HIV Detector

Researchers race to bring cheap HIV testing to rural regions of developing countries.

Apr 1, 2010

By Devin Powell
Inside Science News Service



The technology analyzes a small sample of blood drawn by a finger prick. Blood cells flow through a tiny channel, illuminated by a laser beam. A detector watches patterns in the light that bounces off the cells to identify them.

The detector looks for and counts CD4+ T cells, cells in the immune system that are killed by the HIV virus. The World Health Organization recommends that antiretroviral treatment begin when a patient's CD4 count drops below 250.

"The quality of their test is great," said researcher Bernhard Weigl of PATH, a non-profit reviewing a variety of CD4 testing technologies. "If you look at their graph, it pretty much looked like the graph you would get from a big instrument."

PARC's prototype cost about $250 to build, a hundred times cheaper than the large flow cytometers currently in use. Still, getting it to market may prove challenging.

Kiesel is competing against a dozen other groups vying to fill the need for cheap, portable CD4 tests. Other technologies have been under development for years, including a half-dozen recent projects funded by the Bill and Melinda Gates Foundation that include disposable CD4 tester kits as easy to use as a home pregnancy test. Kiesler's laboratory-tested device is a couple of years behind these projects, some of which have been tested in the field in African countries.

None of these devices is currently on the market. Many have been redesigned several times in the quest for commercialization, including a device by the Austin-based biotech company LabNow, which had hoped to have its technology on the market by 2006.

In the end, Weigl suspects that health workers will use some combination of these approaches in the field. Detectors like the one at PARC, with a low cost per person tested, make sense for areas with many cases of HIV, said Weigl. But disposable kits, which cost less initially and require no maintenance, may be a good solution for remote areas with fewer cases.

"I would be surprised if the first technologies aren't out by 2012," said Weigl. "The market is big; you're looking at many millions of users that have to get checked up every few months."

New Message

Please login to post a reply

AGORACOM Quick Tips

Start A New HUB. Control. Quality. Refreshing. ... Start One Now

President's D.D.

New feature: Hub Presidents can add important links here.